Mumbai, April 30 -- The company announced in an exchange filing that the EIR pertains to an inspection conducted by the USFDA at its Oncology Formulation Facility (F-2), which includes both injectable and oral solid formulations. The inspection was carried out from 7 October 2024 to 8 October 2024.

In an earlier filing dated 9th October 2024, the company informed that it had successfully completed the USFDA inspection for its Oncology Formulation Facility (F-2) located at Panelav. The inspection was successfully completed without any Form 483 observation.

Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company that has been at the forefront of healthcare since 1907. Headquartered in India, Alem...